NFE2L2 and lung carcinoma: Some previous studies demonstrated that Nrf2 transient knockdown or selective inhibition through the Keap1 overexpression strongly increased the susceptibility of lung cancer (44) cells to different chemotherapeutics, including cisplatin (45), doxorubicin (2, 46), and etoposide (24, 47, 48).